Regencell Bioscience Holdings Ltd

NASDAQ RGC

Data sourced from iex and EODHD
Download Data

Regencell Bioscience Holdings Ltd Stock-Based Compensation for the year ending June 30, 2023: USD 922.62 K

Regencell Bioscience Holdings Ltd Stock-Based Compensation is USD 922.62 K for the year ending June 30, 2023, a -66.55% change year over year. Stock-Based Compensation represents the cost of employee compensation provided in the form of equity-based instruments, such as stock options or restricted stock units.
  • Regencell Bioscience Holdings Ltd Stock-Based Compensation for the year ending June 30, 2022 was USD 2.76 M, a 0.00% change year over year.
  • Regencell Bioscience Holdings Ltd Stock-Based Compensation for the year ending June 30, 2021 was USD 0.00, a 0.00% change year over year.
  • Regencell Bioscience Holdings Ltd Stock-Based Compensation for the year ending June 30, 2020 was USD 0.00.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email